"God made the plant." It's a simple observation that opens the door to a much bigger conversation about the evolution of cannabinoids, science, and the future of medicine.
What if compounds found in cannabis could lead to new approaches to treating disease?
In this episode of the Hatch Podcast, producer Tim Scott sits down with Christopher St. Pierre, CEO of Oscity BioSciences, to explore how a company based in Foley, Alabama, is working to bring cannabinoid-based compounds into the world of pharmaceutical development.
This episode is part of our Hatch Bessel 3 series, highlighting the innovative companies and entrepreneurs involved in Hatch's biotech accelerator program.
Chris shares the story behind Oscity, the science of co-crystals, and how the company's patented technology aims to improve the stability and potential pharmaceutical applications of cannabinoids.
The conversation also explores the therapeutic possibilities of these compounds, the challenges of developing new medicines, and what it takes to build a biotechnology company along Alabama's Gulf Coast.
WHAT YOU WILL LEARN
FEATURED IN THIS EPISODE
Christopher St. Pierre
CEO, Oscity BioSciences
Connect with Christopher on LinkedIn
LEARN MORE
Oscity BioSciences
https://oscity.com
Hatch Fairhope
https://hatchfairhope.com
Hatch Events & Meetups
https://hatchfairhope.com/events
Produced by Tim Scott
Interested in starting a podcast? Learn more at:
https://timscott.me